Kelly Lauren, McGrath Sarah, Rodgers Lewis, McCall Kathryn, Tulunay Virlan Aysin, Dempsey Fiona, Crichton Scott, Goodyear Carl S
Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK.
Medannex Ltd, Fountainbridge, Edinburgh, UK.
Immunology. 2022 May;166(1):2-16. doi: 10.1111/imm.13455. Epub 2022 Mar 1.
Annexin-A1 has a well-defined anti-inflammatory role in the innate immune system, but its function in adaptive immunity remains controversial. This glucocorticoid-induced protein has been implicated in a range of inflammatory conditions and cancers, as well as being found to be overexpressed on the T cells of patients with autoimmune disease. Moreover, the formyl peptide family of receptors, through which annexin-A1 primarily signals, has also been implicated in these diseases. In contrast, treatment with recombinant annexin-A1 peptides resulted in suppression of inflammatory processes in murine models of inflammation. This review will focus on what is currently known about annexin-A1 in health and disease and discuss the potential of this protein as a biomarker and therapeutic target.
膜联蛋白A1在先天免疫系统中具有明确的抗炎作用，但其在适应性免疫中的功能仍存在争议。这种糖皮质激素诱导蛋白与一系列炎症性疾病和癌症有关，并且在自身免疫性疾病患者的T细胞上被发现过表达。此外，膜联蛋白A1主要通过其信号传导的甲酰肽受体家族也与这些疾病有关。相比之下，在小鼠炎症模型中，用重组膜联蛋白A1肽进行治疗可抑制炎症过程。本综述将聚焦于目前已知的膜联蛋白A1在健康和疾病中的情况，并讨论这种蛋白质作为生物标志物和治疗靶点的潜力。
